XTXXF Adastra Holdings Ltd. IFRS Annual reports only
Pharmaceutical Preparations · OTC · SEC CIK 1891512 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2022-12-31 (FY2022), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2022*2022-12-31 | FY2021*2021-12-31 | FY2020*2020-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | 13.30M | 5.63M | 2.50M |
| Cost of revenue | 7.18M | 3.68M | 1.71M |
| Gross profit | 6.11M | 1.94M | 785,581 |
| R&D expense | 0 | 89,268 | 181,750 |
| Operating income | -799,996 | -2.39M | -7.17M |
| Interest expense | 343,918 | 276,597 | 399,248 |
| Pretax income | -4.34M | -2.76M | -7.62M |
| Income tax | -56,000 | -15,000 | 0 |
| Net income | -4.28M | -2.75M | -7.62M |
| EBITDA | -298,632 | -2.12M | -7.07M |
| EPS (basic) | -0.07 | -0.05 | -0.19 |
| EPS (diluted) | -0.07 | -0.05 | -0.19 |
| Weighted avg. shares (diluted) | 59.23M | 50.23M | 39.70M |
| Balance sheet | |||
| Cash & equivalents | 1.01M | 744,541 | 1.15M |
| Receivables | 3.56M | 1.50M | 972,680 |
| Inventory | 4.01M | 1.83M | 1.42M |
| Current assets | 9.00M | 4.22M | 3.70M |
| PP&E, netmay include right-of-use assets (IFRS) | 9.73M | 9.77M | 10.04M |
| Goodwill | 9.44M | 11.11M | 0 |
| Intangibles | 3.13M | 3.54M | 0 |
| Total assets | 31.80M | 28.76M | 13.74M |
| Current liabilities | 12.66M | 5.34M | 3.59M |
| Total liabilities | 13.57M | 6.38M | 3.65M |
| Shareholders' equity | 18.23M | 22.37M | 10.09M |
| Shares outstanding | 55.97M | 65.97M | — |
| Cash flow statement | |||
| Operating cash flow | 1.32M | -1.05M | -2.81M |
| Capital expenditure | 625,037 | 581,079 | 1.83M |
| Free cash flow | 694,074 | -1.64M | -4.63M |
| Investing cash flow | -1.03M | -262,811 | -1.82M |
| Financing cash flow | -22,548 | 915,984 | 3.40M |
| Depreciation & amortization | 501,364 | 272,616 | 92,700 |
| Stock-based compensation | 138,713 | 890,523 | 5.33M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.